16 Best Large-Cap Value Stocks To Invest In in 2024

In This Article:

In this piece, we will take a look at the 16 best large cap value stocks to invest in in 2024. If you want to skip our overview of the latest stock market news, then you can skip ahead to 5 Best Large-Cap Value Stocks To Invest In in 2024.

The stock market of 2024 is driven by the same trends that saw investors glued to their screens in 2023. The primary themes in the market right now are artificial intelligence and interest rate cuts, with the final week of February providing investors with key data points and news on both fronts.

Before we get to the news, it's important to see how large cap stocks are fairing these days. These stocks are typically sizeable, mature, and established companies that command strong market positions along with comforting balance sheets. Like other stocks, their performance is also tied to the stock market, and large cap stocks typically attract investors during economic downturns or shaky conditions as they offer comfort with their ability to hedge against major losses.

Diving deeper into large cap stocks, these can be divided either along their industries or their fundamentals to further fine tune any performance expectations. Large cap stocks in stable sectors such as consumer defensive, the likes of the tobacco giant Philip Morris International Inc. (NYSE:PM) or the consumer goods behemoth Unilever PLC (NYSE:UL) are sizeable entities whose global brand following enables investors to rest in comfort knowing that even if the stock and revenue are down in a recession, both will pick up ones the economic winds become more favorable.

On the flip side, large cap stocks belonging to high risk sectors such as biotechnology are significantly vulnerable to market whims as well as any whiff that investors might get about potential troubles. For instance, consider the large cap biotechnology stocks Moderna, Inc. (NASDAQ:MRNA) and BioNTech SE (NASDAQ:BNTX). These two stocks are household names due to their coronavirus vaccine, but despite being multi billion dollar firms, the shares have painted quite an eye watering performance if we consider their performance over the course of the past couple of years.

In fact, the risky nature of these large cap stock industries means that investors have to be on constant watch out for any headwinds that could affect business performance. For Moderna, this came in the form of a report in February 2024 that its vaccine for a respiratory virus had demonstrated reduced efficacy. The shares tumbled 7% on that day, and overall, the stock is down 22% year to date, proving that just because a stock is a large cap does not mean that it will always remain stable. Similarly, BioNTech's stock is down by nearly 15% during its latest earnings report that saw the firm stress that it would return to growth in 2025 after it scales up oncology products to mitigate the effects of a bottoming out of its COVID vaccine market.